Nomigran

Route of administration: Nasal

• Single-dose of 10 mg of nasal spray.
• The maximum dose in a 24 hour period: 30 mg; separate doses by at least one hour or as directed by the physician.

Use in children and adolescents: Sumatriptan is not recommended for use in patients younger than 18 years of age.

Common side effects: Unusual or unpleasant taste in the mouth; pain, burning, numbness, or tingling in the nose or throat; runny or stuffy nose after using the nasal medicine.

Rare side effects: Anxiety, burning sensation, discomfort of the nasal cavity and throat, general feeling of illness or tiredness & vision changes.

No specific data is available on the overdose of Sumatriptan 10 mg nasal spray.

Sumatriptan is indicated for acute treatment of migraine with or without aura in adults. 

Limitations of Use:

• Use only if a clear diagnosis of migraine headache has been established.
• Not indicated for the prophylactic therapy of migraine attacks.
• Not indicated for the treatment of cluster headache.

Sumatriptan Nasal Spray is an aqueous suspension of microfine Sumatriptan BP 10 mg for topical administration to the nasal mucosa by means of a metering, atomizing spray pump. Sumatriptan binds with high affinity to human cloned 5 HT_1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5 HT_1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

5-HT Agonists